City Pharma Limited announced its entry into the direct marketing sector as of January 1, 2025, as part of its 2030 vision, “From Care to Treatment.” This strategic shift will allow the company to deliver high quality pharmaceutical products directly to the public across Pakistan.
According to a PSX filing on Monday, Citi Pharma has appointed Aamir Shahzad as chief commercial officer (CCO) to lead the commercialization initiative. Shahzad has 28 years of experience at major pharmaceutical companies, including Barrett Hodgson, Hilton Pharma and Bristol-Myer Squibb.
It will focus on positioning Citi Pharma as a leading pharmaceutical provider in Pakistan, offering affordable insulin, biological products and solutions to meet the country’s healthcare needs.
Citypharma’s product portfolio will include generic formulations such as antibiotics to treat bacterial infections, cardiovascular drugs, anti-diabetes drugs, analgesics and antipyretics to manage pain and fever, and respiratory treatments for asthma and other chronic conditions, providing comprehensive healthcare solutions.
In biotechnology, the company will prioritize diabetes management, vaccines, and monoclonal antibodies for diseases such as cancer and arthritis. Specialized oncology products will ensure that cancer treatment is easy and affordable.
The company aims to become one of the largest pharmaceutical companies in Pakistan by 2030, with a complete value chain from API production to specialty formulations, while also expanding its presence in international markets.